What is the official website of Novartis Israel ?

The official website of Novartis Israel is https://www.novartis.com/il-he/.

What is Novartis Israel's cybersecurity risk score?

Novartis Israel has an AI-generated cybersecurity risk score of 752 out of 1000, indicating a Fair security posture according to Rankiteo's assessment.

How many security incidents has Novartis Israel experienced?

According to Rankiteo, Novartis Israel currently holds 0 security badges, indicating that no recognized compliance certifications are currently verified for the organization.

Has Novartis Israel been affected by any supply chain cyber incidents ?

According to Rankiteo, Novartis Israel has not been affected by any supply chain cyber incidents, and no incident IDs are currently listed for the organization.

Does Novartis Israel have SOC 2 Type 1 certification ?

According to Rankiteo, Novartis Israel is not certified under SOC 2 Type 1.

Does Novartis Israel have SOC 2 Type 2 certification ?

According to Rankiteo, Novartis Israel does not hold a SOC 2 Type 2 certification.

Does Novartis Israel comply with GDPR ?

According to Rankiteo, Novartis Israel is not listed as GDPR compliant.

Does Novartis Israel have PCI DSS certification ?

According to Rankiteo, Novartis Israel does not currently maintain PCI DSS compliance.

Does Novartis Israel comply with HIPAA ?

According to Rankiteo, Novartis Israel is not compliant with HIPAA regulations.

Does Novartis Israel have ISO 27001 certification ?

According to Rankiteo,Novartis Israel is not certified under ISO 27001, indicating the absence of a formally recognized information security management framework.

Which industry does Novartis Israel operate in ?

Novartis Israel operates primarily in the Pharmaceutical Manufacturing industry.

How many employees does Novartis Israel have ?

Novartis Israel employs approximately 41 people worldwide.

Does Novartis Israel own any subsidiaries ?

Novartis Israel presently has no subsidiaries across any sectors.

How many LinkedIn followers does Novartis Israel have ?

Novartis Israel's official LinkedIn profile has approximately 980 followers.

What is the NAICS classification code for Novartis Israel ?

Novartis Israel is classified under the NAICS code 3254, which corresponds to Pharmaceutical and Medicine Manufacturing.

Does Novartis Israel have a Crunchbase profile ?

No, Novartis Israel does not have a profile on Crunchbase.

Does Novartis Israel have a LinkedIn profile ?

Yes, Novartis Israel maintains an official LinkedIn profile, which is actively utilized for branding and talent engagement, which can be accessed here: https://www.linkedin.com/company/novartis-israel.

How many cybersecurity incidents has Novartis Israel experienced ?

As of August 19, 2026, Rankiteo reports that Novartis Israel has experienced 2 cybersecurity incidents.

How many peer or competitor companies does Novartis Israel have ?

Novartis Israel has an estimated 5,728 peer or competitor companies worldwide.

What types of cybersecurity incidents has Novartis Israel faced ?

Incident Types: The types of cybersecurity incidents that have occurred include Breach and Cyber Attack.

NEWRankiteo Cyber Underwriting Desktop - Score, price, and bind from your desktop

WindowsmacOSLinux

Download

Badge your company to reduce your risk score and your cyber insurance costs!

Link verified badges to your company page to build trust with insurers and customers.

Apply now and get your badge!

Internal validation & live display

Insurers and partners see a safer profile

Faster underwriting decisions

Trusted by insurers. Chosen by leaders.

Proud contributor to the Society of Actuaries.

Novartis Israel

Boost Score +25 with badge (5 left)

752

/1000

Fair

777

/1000

Fair

Novartis Israel Vendor Cyber Rating & Cyber Score

novartis.com

Add Your Compliance Badge

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. Around 108,000 people of more than 140 nationalities work at Novartis around the world. See our community guidelines: http://bit.ly/2JnT2CP

Novartis Israel A.I CyberSecurity Scoring

Scoring History

Novartis Israel

Novartis Israel CyberSecurity News & History

Past Incidents

Attack Types

Entity

Type

Severity

Impact

Seen

Blog Details

Supply Chain Source

Incident Details

View

Novartis

Breach

2/2026

NOV1774449180

Novartis Israel

Cyber Attack

100

06/2022

NOV21267722

Loading…

A.I.

Novartis Israel Company Scoring based on AI Models

Cyber Incidents Likelihood 3 - 6 - 9 months

Actual

Prediction

Incident Predictions locked

Access Monitoring Plan

A.I Risk Score Likelihood 3 - 6 - 9 months

Actual

Prediction A

Prediction B

Prediction C

Prediction D

A.I. Risk Score Predictions locked

Access Monitoring Plan

Loading…

Underwriter Stats for Novartis Israel

Incidents vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Israel in 2026.

Incidents vs All-Companies Average (This Year)

No incidents recorded for Novartis Israel in 2026.

Incident Types Novartis Israel vs Pharmaceutical Manufacturing Industry Avg (This Year)

No incidents recorded for Novartis Israel in 2026.

Incident History - Novartis Israel (X = Date, Y = Severity)

Loading…

SUBSIDIARY

Novartis Israel Subsidiaries

Novartis Israel

Pharmaceutical Manufacturing

Website: https://www.novartis.com/il-he/

Company Size: 41

NovartisPharmaceutical Manufacturing

Novartis IndiaPharmaceutical Manufacturing

Novartis ItaliaPharmaceutical Manufacturing

Novartis MéxicoPharmaceutical Manufacturing

Novartis NorgePharmaceutical Manufacturing

Novartis BeluxPharmaceutical Manufacturing

Novartis DanmarkPharmaceutical Manufacturing

Novartis SverigePharmaceutical Manufacturing

Novartis FinlandPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis MagyarországPharmaceutical Manufacturing

Novartis in SloveniaPharmaceutical Manufacturing

Novartis SerbiaPharmaceutical Manufacturing

Novartis BrasilPharmaceutical Manufacturing

Novartis Hong KongPharmaceutical Manufacturing

Novartis SciencePharmaceutical Manufacturing

Novartis Gene TherapiesBiotechnology Research

Novartis SlovakiaPharmaceutical Manufacturing

Novartis MedicalPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis EspañaPharmaceutical Manufacturing

Novartis NederlandPharmaceutical Manufacturing

Novartis Nederland - NeurologieGeneesmiddelenproductie

Novartis Nederland - OncologieGeneesmiddelenproductie

Novartis Nederland - HematologieGeneesmiddelenproductie

Novartis Nederland - ReumatologieGeneesmiddelenproductie

Novartis Nederland - DermatologieGeneesmiddelenproductie

Novartis Nederland - Cardiovascular, Renal & Metabolism Geneesmiddelenproductie

Novartis USPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis DeutschlandPharmaceutical Manufacturing

Novartis ColombiaPharmaceutical Manufacturing

Novartis PortugalPharmaceutical Manufacturing

Novartis, Australia & New ZealandPharmaceutical Manufacturing

Novartis CanadaPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis Ireland Pharmaceutical Manufacturing

Novartis Gulf | نوفارتس الخليجPharmaceutical Manufacturing

Novartis US MedicalPharmaceutical Manufacturing

Novartis SlovakiaPharmaceutical Manufacturing

Novartis RomâniaPharmaceutical Manufacturing

Novartis ArgentinaPharmaceutical Manufacturing

Novartis SingaporePharmaceutical Manufacturing

Loading…

Novartis Israel Similar Companies

Dr. Reddy's Laboratories

drreddys.com

Established in 1984, we are a global pharmaceutical company headquartered in Hyderabad, India. Driven by our purpose of ‘Good Health Can’t Wait’, we work to provide access to affordable and innovative medicines. We offer a portfolio of products and services including APIs, generics, branded generics, biosimilars and OTC. Our major markets include USA, India, Russia & CIS countries, China, Brazil and Europe. As a company with a history of deep science that has led to several industry firsts, we continue to plan ahead and invest in future growth drivers such as access to novel molecules, digital therapeutics and consumer healthcare. As an early adopter of sustainability and ESG actions, we released our first Sustainability Report in 2004. Our current ESG goals aim to set the bar high in environmental stewardship; access and affordability for patients; diversity; and governance. For more information, log on to: www.drreddys.com. Caution Notice: Dr. Reddy's has been made aware of candidates receiving fraudulent job opportunities from unauthorised recruiting agencies or people impersonating Dr. Reddy's leaders. These fraudulent jobs may be advertised on employment sites or mimic our careers site and company email addresses. Please know that Dr. Reddy's Laboratories has no affiliation or connection to these situations. Dr. Reddy's (and its associated/group companies) follows a formal recruitment process through its own HR department. Please report immediately in case you suspect a fraudulent job. You may raise your concern by: Accessing https://drreddys.ethicspoint.com. Calling on the hotline number. List of hotline numbers are available in https://drreddys.ethicspoint.com. The hotline is available 24x7 in multiple languages. Writing to [email protected] or [email protected]. For our community guidelines on LinkedIn, please visit: https://shorturl.at/LTvNZ

Johnson & Johnson Innovative Medicine

cb jnj.com

At Johnson & Johnson Innovative Medicine, we innovate with purpose, to lead where medicine is going. The experiences of patients around the world inform and inspire our science-based innovations, which continue to change and save lives. Applying rigorous science with compassion, we confidently address the most complex diseases of our time and develop the potential medicines of tomorrow. We are continuously working to develop treatments, aspiring to find cures, pioneering the path from lab to life, and championing patients every step of the way. https://bit.ly/3reuMvK

Catalent

catalent.com

Championing the missions that matter™. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) and trusted partner to pharma, biotech, and consumer health companies worldwide. We put patients first in everything we do, helping people live better and healthier lives through every product we help develop, manufacture and deliver. With over 1,000 active development programs at any given time, we launch over 100 new products and line extensions annually. Catalent has supported half of all FDA approvals over the past decade, and our teams working at over 40 global sites help us produce over 60 billion doses every year. Our strength lies in our people: teams across our more than 40 sites and thousands of passionate scientists and technicians who bring expertise in development sciences, delivery technologies, and multi-modality manufacturing. What unites us is our commitment to championing our partners’ missions as our own, anticipating customer needs, solving complex challenges and ultimately making a difference in the lives of patients across the globe. At Catalent, you will be able to directly have an impact, solving problems and ensuring excellence for our customers. Our focus on delivering meaningful outcomes alongside our customers means your work directly impacts millions of people around the world. Join us in championing the missions that matter. Catalent is headquartered in Tampa, Florida, with over 40 global sites. Visit www.catalent.com to learn more.

MANKIND PHARMA LTD

mankindpharma.com

Mankind Pharma, one of the top 5 leading pharmaceutical companies in India, started its journey in 1995. Today, we have an employee base of over 20,000 and are racing towards $1 Billion. At Mankind, we aspire to aid the community in leading a healthy life by formulating, developing, commercializing, and delivering affordable and accessible medicines that satisfy urgent medical needs. We take great pride in the success of our products ranging from Pharma, OTC and FMCG brands like Manforce Condoms, Manforce Tablets, Manforce Staylong Gel, Unwanted 72, Prega News, Gas-O-Fast, Kaloree 1, Kabzend, Acne Star Gel and many others. Our operations are in 34 overseas destinations across Asia, Africa, South-East Asia, Gulf countries and CIS countries. Our Vision - To be a global pharmaceutical company, most admired for its Affordability, Quality and Accessibility of products. Our Mission - To be able to provide cost-effective, innovation based superior quality pharmaceutical products across the globe, to improve the lives of the patients. Mankind strongly believes and follows its Core Values: 𝐂𝐮𝐬𝐭𝐨𝐦𝐞𝐫 𝐂𝐞𝐧𝐭𝐫𝐢𝐜𝐢𝐭𝐲: Commitment to Customer - Internal and External 𝐐𝐮𝐚𝐥𝐢𝐭𝐲: It is in our DNA to maintain and deliver highest quality standards and products 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐨𝐧: Intensely Research driven organization aiming at product innovation and technology improvements 𝐈𝐧𝐭𝐞𝐠𝐫𝐢𝐭𝐲: Always trustworthy, widely respected to be honest, and believed by everyone 𝐆𝐨 𝐁𝐞𝐲𝐨𝐧𝐝: Aim higher than capabilities 𝐏𝐞𝐨𝐩𝐥𝐞 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐚𝐧𝐝 𝐂𝐨𝐥𝐥𝐚𝐛𝐨𝐫𝐚𝐭𝐢𝐨𝐧: Together we are foreseeing future and diligently stimulating our people in attaining goals

UCB

cb ucb.com

At UCB, we believe everyone deserves to live the best life they can - as free as possible from the challenges and uncertainty of disease. Our purpose is to support people living with severe central nervous system and immunological conditions by delivering meaningful solutions that go beyond medicine. We are driven by the experiences of patients and caregivers, and inspired to pursue innovations that create real value - not just in clinical outcomes, but in everyday moments, dreams pursued, and simple pleasures enjoyed. Our ambition is to unlock transformative science and technologies that respond to unmet needs and elevate lives. From our headquarters in Belgium to nearly 40 countries around the world, we nurture a culture of respect and care. By listening deeply and collaborating across borders and disciplines, we enable cutting-edge research shaped by patients’ needs. Through strong connections with healthcare professionals, partners, and communities, we strive to make a lasting impact - today and into the future. We're inspired by patients, driven by science.

Hikma Pharmaceuticals

cb hikma.com

For almost 50 years, we’ve been creating high-quality medicines and making them accessible to the people who need them. We are a trusted, reliable partner and dependable source of over 800* high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe. We have 29 manufacturing plants, 3 R&D hubs and c9,500 employees worldwide. *As of December 2025 Subscribe to our channel on YouTube https://youtube.com/@hikmapharmaceuticals5668 For all product information and enquiries, please contact us at [email protected]

EMS

cb ems.com.br

Fundada há mais de 60 anos e com capital 100% nacional, a EMS é a líder do mercado farmacêutico brasileiro há 19 anos consecutivos, pertencente ao Grupo NC, um dos maiores conglomerados brasileiros. A empresa ocupa também a liderança no segmento de genéricos desde 2013 (IQVIA 2019) e está entre os maiores laboratórios em preferência prescritiva no Brasil. Tem forte presença em PDVs de todo o país e atuação nas áreas de Prescrição Médica, Genéricos, Marcas, OTC e Hospitalar, fabricando medicamentos para praticamente todas as especialidades da Medicina. Possui fábricas em Hortolândia (SP), Manaus (AM), Brasília (DF) e Jaguariúna (SP). A EMS apoia ações de responsabilidade social dentro e fora do Brasil. Em 2017, por exemplo, o laboratório fechou parceria com a Organização Mundial da Saúde (OMS) para doar 100% do medicamento para erradicar, nos próximos anos, em todo o planeta, a bouba, doença negligenciada. A EMS é a única farmacêutica no mundo a ter abraçado essa causa. O Centro de Pesquisa & Desenvolvimento da EMS no Brasil é o mais moderno da América Latina. Na Itália, a EMS tem o laboratório de pesquisas MonteResearch. O foco de atuação do laboratório é a inovação nas seguintes frentes: inovação incremental; genéricos de alta complexidade; medicamentos biotecnológicos, por meio da empresa Bionovis; e inovação disruptiva, por meio da Brace Pharma, empresa da EMS instalada em 2013 nos Estados Unidos. Ainda, nos EUA, por meio de sua controlada Vero Biotech, localizada em Atlanta, Geórgia, a EMS, recentemente, obteve a aprovação de seu primeiro produto revolucionário submetido à FDA (Food and Drug Administration), posicionando o laboratório como uma empresa de inovação no mercado global. Com aportes frequentes em infraestrutura fabril e em pesquisa de ponta para desenvolver produtos inovadores, eficazes e seguros, a EMS, que já exporta para mais de 40 países, está preparada para continuar cuidando das pessoas que querem viver cada vez mais e melhor.

Servier

servier.com

Founded to serve health 70 years ago, Servier is a global pharmaceutical group governed by a non-profit Foundation that aspires to make a meaningful social impact for patients and for a sustainable world. The Group’s unique governance model preserves its independence and means it can fully serve its vocation of being committed to therapeutic progress to serve patient needs while adopting a long-term vision. Its employees are fully committed to this shared vocation, which serves as a source of inspiration every day. A world leader in cardiometabolism and venous diseases, Servier has made a major shift into oncology, which represents a new pillar of strategic growth. The Group devotes close to 70% of its R&D budget to this field, with the ambition of becoming a focused and innovative player in the development of treatments targeting rare cancers. Neurology will constitute a future growth driver. Servier is focusing on a limited number of diseases in this area where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To promote widespread access to quality care at a lower cost, the Group also offers a range of quality generic drugs covering most pathologies, leveraging well-known brands in France, and Eastern Europe. In all these areas, the Group takes patient considerations into account at every stage of the medicine life cycle. Headquartered in France, Servier relies on committed teams and strong geographical footprint; its medicines are available in close to 140 countries. In 2023/2024, the Group achieved sales revenue of €5.9 billion and EBITDA of €1.3 billion in 2024 (22.2%). Today, the Group employs over 22,000 people worldwide. -- To report a suspected adverse event with a Servier drug, please visit servier.com

Merck Group

merckgroup.com

This channel is not intended for U.S. and Canadian visitors. Merck operates in the U.S. and Canada as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Electronics in Electronics. An unaffiliated and unrelated company, Merck & Co., Inc., Kenilworth, NJ, US holds the rights in the trademark MERCK in the U.S. and Canada. _______________________________ We are Merck, a leading global science and technology company headquartered in Germany. We are curious explorers, courageous pioneers, and ingenious inventors. Our colleagues across the globe love innovating with science and technology to enrich people’s lives with our solutions in Life Science, Healthcare, and Electronics. Together, we dream big and are passionate about caring for our rich mix of people, customers, patients, and the planet. We believe in the positive power of science and technology. It has determined our actions since 1668 and inspires us to continue researching for a future worth living. As a family-owned company with over 350 years of experience, we stand for sustainability, responsibility, and innovative strength. We take pride in being a diverse and inclusive company that values and fosters the talents and abilities of our employees. That's why we are always looking for curious minds that see themselves imagining the unimaginable with us. Work your Magic and join Merck. Legal Disclaimer: www.merckgroup.com/en/legal-disclaimer.html Data Privacy Declaration: www.merckgroup.com/en/privacy-statement

Loading…

NEWS

Novartis Israel CyberSecurity News

Latest updates, reports, and threat intel affecting the global network.

December 03, 2025 08:00 AM

JPMorgan's tech team hired an Amazon director and Pfizer executive as MDs

JPMorgan has been hiring multiple senior technologists, but they're not all coming from finance. Two new managing directors (MDs),...

Read Article

May 20, 2025 07:00 AM

Women Know Cyber: 150 Fascinating Females Fighting Cybercrime

Role models for students, parents, educators, and the cybersecurity community Sponsored by Secureworks.

Read Article

July 19, 2021 07:00 AM

Rapid7 acquires IntSights for close to $400 million

The Israeli cybersecurity company is set to become Rapid7's R&D center in Israel)

Read Article

July 15, 2021 07:00 AM

Rapid7 in advanced talks to acquire Israel's IntSights for $350 million

The Israeli cybersecurity company has raised $70 million to date and counts Forbes, Novartis and Ford among its clients)

Read Article

Loading…

CVE

Latest

Global CVEs (Not Company-Specific)

CVE-2026-66591

SUMMARY

Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting') vulnerability in David Lingren Media LIbrary Assistant allows Stored XSS. This issue affects Media LIbrary Assistant: from n/a through 3.39.

Published

Date2026-08-18

Updated

Date2026-08-18

RISK INFORMATION (Score: 6.5)

cvss3

Base Score: 6.5

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:R/S:C/C:L/I:L/A:L

Impact Score

3.7

Exploitability

2.3

REFERENCES

https://patchstack.com/database/wordpress/plugin/media-library-assistant/vulnerability/wordpress-media-library-assistant-plugin-3-39-cross-site-scripting-xss-vulnerability?_s_id=cve

CVE-2026-66589

SUMMARY

Missing Authorization vulnerability in Kings Plugins B2BKing allows Exploiting Incorrectly Configured Access Control Security Levels. This issue affects B2BKing: from n/a through 5.2.30.

Published

Date2026-08-18

Updated

Date2026-08-18

RISK INFORMATION (Score: 5.4)

cvss3

Base Score: 5.4

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:N

Impact Score

2.5

Exploitability

2.8

REFERENCES

https://patchstack.com/database/wordpress/plugin/b2bking-wholesale-for-woocommerce/vulnerability/wordpress-b2bking-plugin-5-2-30-broken-access-control-vulnerability?_s_id=cve

CVE-2026-27365

SUMMARY

Improper Neutralization of Input During Web Page Generation ('Cross-site Scripting') vulnerability in PublishPress PublishPress Series allows Stored XSS. This issue affects PublishPress Series: from n/a through 2.17.0.

Published

Date2026-08-18

Updated

Date2026-08-18

RISK INFORMATION (Score: 5.9)

cvss3

Base Score: 5.9

Complexity: LOW

CVSS:3.1/AV:N/AC:L/PR:H/UI:R/S:C/C:L/I:L/A:L

Impact Score

3.7

Exploitability

1.7

REFERENCES

https://patchstack.com/database/wordpress/plugin/organize-series/vulnerability/wordpress-publishpress-series-plugin-2-17-0-cross-site-scripting-xss-vulnerability?_s_id=cve

CVE-2026-73974

SUMMARY

linuxfabrik-lib provides Python modules for database access, caching, shell execution, and API integrations, and Linuxfabrik Monitoring Plugins uses its shared testing helper across check plugins. Prior to linuxfabrik-lib 6.1.0 and Linuxfabrik Monitoring Plugins 7.0.0, lib.lftest.test() treated the first or second element of a --test CSV argument as a filesystem path and returned the file contents as simulated standard output or standard error without path confinement. The hidden but production-accessible --test argument was accepted by sudo-authorized plugins, so an attacker controlling the nagios or icinga account could use check-plugins/deb-updates/deb-updates with its default QUERY=1 to disclose every line of a root-readable file. Approximately 22 other plugins exposed filtered content or a root file existence and readability oracle through the same helper, while check-plugins/network-bonding/network-bonding and check-plugins/openstack-swift-stat/openstack-swift-stat had direct read paths that bypassed the helper. The library fix confines fixture reads to the invoking plugin's unit-test directory and refuses unsafe anchors, and the plugin fix routes the two bypasses through that helper. These issues are fixed in linuxfabrik-lib 6.1.0 and Linuxfabrik Monitoring Plugins 7.0.0.

Published

Date2026-08-18

Updated

Date2026-08-18

RISK INFORMATION (Score: 5.5)

cvss3

Base Score: 5.5

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:H/I:N/A:N

Impact Score

3.6

Exploitability

1.8

REFERENCES

CVE-2026-73973

SUMMARY

Linuxfabrik Monitoring Plugins provides monitoring plugins for Icinga, Nagios, and related systems. Prior to version 7.0.0, check-plugins/logfile/logfile accepted a free-form --filename path and opened it as root when invoked through the shipped nagios or icinga sudoers allowlist, without confining the resolved path to /var/log. An attacker who controls the monitoring account can select a root-readable file such as /etc/shadow and use --warning-regex . while leaving SUPPRESS_OUTPUT false, causing each nonempty line to be collected in warn_matches and returned through lib.base.oao(). The vulnerable flow passes the expanded scan_path directly to open(), and neither real-path containment nor an allowlist protects the sink. The same fix also confines mysql-logfile and openvpn-client-list paths, allows only documented log roots, and resolves symlinks and parent-directory traversal before checking containment. This issue is fixed in version 7.0.0.

Published

Date2026-08-18

Updated

Date2026-08-18

RISK INFORMATION (Score: 5.5)

cvss3

Base Score: 5.5

Complexity: LOW

CVSS:3.1/AV:L/AC:L/PR:L/UI:N/S:U/C:H/I:N/A:N

Impact Score

3.6

Exploitability

1.8

REFERENCES

Loading…

API

Access Data Using Our API

Get company history

curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'

Try It API Documentation Rapid

MEASURE

What Do We Measure ?

Incident

Finding

Grade

Digital Assets

Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.

These are some of the factors we use to calculate the overall score:

Network SecurityIdentify exposed access points, detect misconfigured SSL certificates, and uncover vulnerabilities across the network infrastructure.

SBOM (Software Bill of Materials)Gain visibility into the software components used within an organization to detect vulnerabilities, manage risk, and ensure supply chain security.

CMDB (Configuration Management Database)Monitor and manage all IT assets and their configurations to ensure accurate, real-time visibility across the company's technology environment.

Threat IntelligenceLeverage real-time insights on active threats, malware campaigns, and emerging vulnerabilities to proactively defend against evolving cyberattacks.

Rankiteo

By Rankiteo

★ ★ ★ ★ ★

View on G2.com

Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.

View latest plans →View all security reports →

MILESTONEG

Users
Love Us

Loading…